Merck & Co. (MRK) Update

Establishing 2022 and 2023 Estimates, Maintaining Outperform Rating, Setting $85 Price Target

Following the spin-off of Organon, Merck is focused on growing its pharmaceuticals business to offset the looming loss of exclusivity on its $5 billion Januvia/Janumet franchise and others that will follow as the decade progresses.  Investors’ concerns about the impact of LOE contributed to the stock’s underperformance in 21H2.  Some investors worry that Merck’s pipeline will not sustain its revenues and profits.  My estimates anticipate that both will decline slightly in 2023.

Even so, Merck has advanced its pipeline meaningfully and business development activities could further enhance its revenue and earnings prospects.  The spin-off of Organon has increased Merck’s organizational capacity, opening the door wider potentially to larger acquisitions.  In November, Merck acquired Acceleron Pharma for $11.5 billion, its largest in more than a decade.  Merck will likely make additional acquisitions in 2022 and beyond.

Based upon the company’s 2022 financial guidance, I project that Merck will achieve GAAP EPS of $5.83 in 2022, giving the stock a forward multiple of 13.4 times, modestly below the estimated peer group average of 16-17 times.  The discount reflects in part market expectations of modestly lower earnings in 2023, industrywide concerns about drug pricing, concerns about the potential of its pipeline and uncertainty about the impact of acquisitions.

Despite this sentiment, the stock has outperformed during this recent correction and its outlook should improve as Merck showcases its pipeline and announces new business development initiatives.  I am maintaining my outperform rating and setting a price target of $85.  With this price target and the stock’s 3.5% yield, its potential 12-month total return is 12.8%.

This is a summary of my recent update report on Merck & Co., Inc. (MRK). Reach out to me for a copy of the full report.

March 15, 2022

Stephen P. Percoco
Lark Research
839 Dewitt Street
Linden, New Jersey 07036
(908) 975-0250

© 2015-2024 by Stephen P. Percoco, Lark Research.   All rights reserved.

This blog post (as with all posts on this website) represents the opinion of Lark Research based upon its own independent research and supporting information obtained from various sources. Although Lark Research believes these sources to be reliable, it has not independently confirmed their accuracy. Consequently, this blog post may contain errors and omissions. Furthermore, this blog post is a summary of a recent report published on this subject and that report provides a more complete discussion and assessment of the risks and opportunities of any investment securities discussed herein. No representation or warranty is expressed or implied by the publication of this blog post. This blog post is for informational purposes only and shall not be construed as investment advice that meets the specific needs of any investor. Investors should, in consultation with their financial advisers, determine the suitability of the post’s recommendations, if any, to their own specific circumstances. Lark Research is not registered as an investment adviser with the Securities and Exchange Commission, pursuant to exemptions provided in the Investment Company Act of 1940. This blog post remains the property of Lark Research and may not be reproduced, copied or similarly disseminated, in whole or in part, without its prior written consent.

This entry was posted in Health Care, MRK and tagged , . Bookmark the permalink.